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Supplementary Figure 1. Validation of 12 DMLs by pyrosequencing 
Methylation at Day0 and Day14 in four MSC donors measured by pyrosequencing for 12 DMLs. A. 
ACAN cg01706824. B. SOX9 cg19298400. C. C2ORF82 cg07623116. D. C2ORF82 cg13047596. E. 
COL11A2 cg27512176, cg12472351 and cg19628686. F. FMOD cg15824962. G. MIA cg25152942. H. 
EXT1 cg22271457. I. SERPINA3 cg08057786 and cg06190732. For some pyrosequencing assays 
additional adjacent CpGs were also measured (denoted by + or -). The sequence analysed is 
reproduced below the plot with the CpGs in bold and the original DML underlined. Significant 
differences between Day0 and Day14 were assessed by two-tailed paired Students t-test. 
Supplementary Figure 2. Comparison of the extent of methylation changes per MSC donor during 
chondrogenesis  
Beta value methylation change at Day14 for each MSC donor DML compared to the average beta 
methylation of all donors at Day0. A. Donor 1 vs Donor 2. B. Donor 1 vs Donor 3. C. Donor 2 vs Donor 
3. Red indicates >10% hypomethylation, blue >10% hypermethylation at Day14 for both donors. 
Supplementary Table 1. List of differentially methylated loci (DML) during MSC chondrogenesis 
Column heading descriptions: 450K array CpG ID; Day0 average beta methylation; Day14 average beta 
methylation; change in methylation at Day14 vs Day0; adjusted P value; chromosome; base position; 
DNA strand; CpG island identifier; the relation to CpG island; the UCSC RefGene name; the UCSC 
RefGene accession number and the UCSC RefGene group in relation to gene loci. 
Supplementary Table 2. List of differentially methylated regions (DMR) during MSC chondrogenesis 
Column heading descriptions: DMRcate DMR number; DMR genomic location; chromosome; DMR 
start base position; DMR end base position; DMR size (bases); number of 450K array CpGs within DMR; 
minimum FDR of the smoothed estimate - where FDR smoothing results in increased power and 
cleaner spatial separation of signals from noise; Stouffer summary transform of the individual CpG 
FDRs – where the Stouffer method generates a more conservative combined statistic from 
independent significant test p values; maximum beta methylation change within the DMR; average 
beta methylation change within the DMR; gene promoters overlapping with the DMR. 
Supplementary Table 3. Intersection of DML during MSC chondrogenesis and DML in osteoarthritis 
Column heading descriptions: 450K array CpG ID; Day0 average beta methylation; Day14 average beta 
methylation; change in methylation at Day14 vs Day0; adjusted P value; chromosome; base position; 
DNA strand; CpG island identifier; the relation to CpG island; the UCSC RefGene name; the UCSC 
RefGene accession number and the UCSC RefGene group in relation to gene loci. 
Supplementary Table 4. Sample information 
Supplementary Table 5. Pyrosequencing primers 
Sequences of forward, biotinylated-reverse (*) and sequencing primers for pyrosequencing including 











































































































































































































































































































































































































































































































































































Samples Sex Age Treatment
MSC_Donor1_Day0_1 F 22 Day0 undifferentiated
MSC_Donor1_Day0_2 F 22 Day0 undifferentiated
MSC_Donor1_Day0_3 F 22 Day0 undifferentiated
MSC_Donor1_Day14_1 F 22 Day14 chondrogenic
MSC_Donor1_Day14_2 F 22 Day14 chondrogenic
MSC_Donor1_Day14_3 F 22 Day14 chondrogenic
MSC_Donor2_Day0_1 F 24 Day0 undifferentiated
MSC_Donor1_Day0_4 F 22 Day0 undifferentiated
MSC_Donor3_Day0_4 F 24 Day0 undifferentiated
MSC_Donor4_Day14_1 M 22 Day14 chondrogenic
MSC_Donor2_Day0_2 F 24 Day0 undifferentiated
MSC_Donor2_Day14_1 F 24 Day14 chondrogenic
Supplementary Table 4
CpG Primer Primer sequence
ACAN cg01706824 F TTTTTTTGGGATACTGGAGTTAAATATATAA
R *CTAACAACCCCCTCTCACT
Sequencing GTGTTAGGGATGATAAATTTT Sequence to analyze: TYGGGAATTT AGTT 
SOX9 cg19298400 F ATTAGATATTTTAGGGTTGGAATTTTAAGT
R *CCCTCCTACCTCTACAAATAAATATCAT
Sequencing AGGGTATTTTTGGTTTATATG Sequence to analyze: ATTTAYGGTA ATTYGAGGTT ATTTATAGTA A
C2ORF82 cg07623116 F GGGAGTTTAGTTAAGGTTAGTGGATTGAA
R *TCCCACCTCTAAACCCTCAAAATTCTATCA
Sequencing TGGGTGGGAAGTTGA Sequence to analyze: GTAGGGTYGA GGTAAGTTTT TAG
C2ORF82 cg13047596 F TGTTTTTAGGTTTAGGAAAGTAGGT
R *CAAAACCAAACAAAATACCATCCTAAC
Sequencing TTTTTATTGTTTTGAAGTTAATTAG Sequence to analyze: YGTAGTTTTT YGTGYGTTTY GTTYGTYGTT GTTTTTATTT T
COL11A2 cg27512176, cg12472351 and cg19628686 F TGTGGGTAGGTTGTTTATATGAT 
R *AACCCCCACCTAAACCTAAC 
Sequencing TTTGTGTTTTTGTTTTATTTATTTT Sequence to analyze: TYGTTTTTTA AAGYGGTTTT TGTGTGTTGG TGTTTGYGGA GTTGTTATA
FMOD cg15824962 F TGGAAATAAGTGTTTAGAAAGTTGTAAGT
R *CTTCCTACCCTCTAATCTCTCT 
Sequencing AATTAGGTGGTGATTATATT Sequence to analyze: T TYGGGGAAG YGGGGAGGGY GATGTAGGTA TATATG
MIA cg25152942 F TGGGATTTTGTTTAGTTTAAGGTTTAGTA
R *ATTCAATTCCATCTTCTCTTAAATTAACT
Sequencing GGTGGTTTTTTTTATAGGTTT Sequence to analyze: TTTYGTTTTT GTGGTTAGAG GGGATAG
EXT1 cg22271457 F ATGTAGGGGATAGTTATTATTGTGTTTA
R *TTCTAAATTTTCCTAAAAAATCCAAATTAT
Sequencing GGTGAAATTTTTGAGATGAG Sequence to analyze: AYGGATGAAA TATGTTGAGA TATTTAA
SERPINA3 cg08057786 and cg06190732 F GTTTTTTTGATTTTGGAGGAAGAGA
R *CAAAAAACTCCTCCCCCTACTT
Sequencing ATTTGAGTAGGTTTAATAAGT Sequence to analyze: TYGTATTATT AGAAATTATT ATTTGGTTAT TTTTAGTTYG AGAATAGAAT ATTTGGTTGT TTTG
Supplementary Table 5
